Corcept Therapeutics (NASDAQ:CORT) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending approval of relacorilant combined with nab-paclitaxel for patients with platinum-resistant ovarian cancer.
Abeona Therapeutics (NASDAQ:ABEO) announced that Ultragenyx Pharmaceutical received U.S. Food and Drug Administration approval for FAYUVI (rebisufligene etisparvovec-hopf), a gene therapy for Sanfilippo syndrome type A.
BlossomHill Therapeutics (NASDAQ:BLSM) reported second quarter 2026 financial results and pipeline progress, highlighting its strengthened cash position following an upsized initial public offering.
Merck (NYSE:MRK) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending KEYTRUDA (pembrolizumab) combined with Padcev (enfortumab vedotin-ejfv) for adults with resectable muscle-invasive bladder cancer.
Xenon Pharmaceuticals (NASDAQ:XENE) shares declined after the company temporarily paused new patient enrollment in clinical studies evaluating its drug candidate for major depression and bipolar depression.
Novo Nordisk (NYSE:NVO) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending once-weekly Sogroya (somapacitan) for children in Europe with idiopathic short stature and persistent growth disturbance.
The Ensign Group (NASDAQ:ENSG) declared a quarterly cash dividend of $0.0650 per share of common stock, payable on or before October 31, 2026.
Natera (NASDAQ:NTRA) presented new data from its Signatera molecular residual disease (MRD) test at the IASLC 2026 World Conference on Lung Cancer, including results from a 1,129-patient analysis in early-stage non-small cell lung cancer.
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) received authorization from Health Canada for their Omicron XFG-adapted COVID-19 vaccine.
Surgery Partners (NASDAQ:SGRY) updated its 2026 financial outlook following the completed sale of its Idaho Falls facilities to Intermountain Health.
MIRA Pharmaceuticals (NASDAQ:MIRA) submitted a Phase 2a clinical trial protocol for Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) following review and feedback from the U.S. Food and Drug Administration.
Clearmind Medicine (NASDAQ:CMND) reported that its Chief of Global Impact Mary-Elizabeth Gifford participated in a U.S. Food and Drug Administration panel focused on potential future therapeutic use of psychedelic drugs.
-640x360.webp&w=3840&q=75)